Kiniksa Pharmaceuticals International, plc financial data

Symbol
KNSA on Nasdaq
Industry
Pharmaceutical Preparations
Location
23 Old Bond Street, Floor 3, London, United Kingdom
State of incorporation
United Kingdom
Fiscal year end
December 31
Former names
Kiniksa Pharmaceuticals, Ltd. (to 6/28/2024)
Latest financial report
10-Q - Q2 2024 - Jul 25, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 416 % -19%
Quick Ratio 44.7 % +0.4%
Debt-to-equity 21.1 % +25.9%
Return On Equity -2.39 % -104%
Return On Assets -1.98 % -104%
Operating Margin -8.12 % -160%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 510M USD +47.2%
Weighted Average Number of Shares Outstanding, Basic 71M shares +1.55%
Weighted Average Number of Shares Outstanding, Diluted 71M shares -0.88%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 339M USD +20.7%
Research and Development Expense 87.5M USD +25.3%
Operating Income (Loss) -27.5M USD -172%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -18M USD -142%
Income Tax Expense (Benefit) -7.79M USD +95.9%
Net Income (Loss) Attributable to Parent -10.2M USD -104%
Earnings Per Share, Basic -0.14 USD/shares -104%
Earnings Per Share, Diluted -0.14 USD/shares -104%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 99.3M USD -11.8%
Cash, Cash Equivalents, and Short-term Investments 219M USD +18.3%
Accounts Receivable, after Allowance for Credit Loss, Current 20.5M USD -17%
Inventory, Net 34.9M USD +45.5%
Assets, Current 301M USD +22.3%
Deferred Income Tax Assets, Net 204M USD +0.24%
Property, Plant and Equipment, Net 625K USD -45%
Operating Lease, Right-of-Use Asset 11.8M USD -10.7%
Other Assets, Noncurrent 7.9M USD +236%
Assets 542M USD +12%
Accounts Payable, Current 7.39M USD +1041%
Employee-related Liabilities, Current 11.5M USD +24.3%
Accrued Liabilities, Current 33.4M USD -5.5%
Contract with Customer, Liability, Current 12K USD -99.7%
Liabilities, Current 84.3M USD +77.6%
Contract with Customer, Liability, Noncurrent 11.8M USD -1.72%
Operating Lease, Liability, Noncurrent 9.32M USD -17.4%
Other Liabilities, Noncurrent 1.93M USD +0.57%
Liabilities 107M USD +47.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -130K USD -1100%
Retained Earnings (Accumulated Deficit) -500M USD -2.09%
Stockholders' Equity Attributable to Parent 435M USD +5.69%
Liabilities and Equity 542M USD +12%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 3.99M USD
Net Cash Provided by (Used in) Financing Activities 3.61M USD +3914%
Net Cash Provided by (Used in) Investing Activities 25.5M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 99.3M USD -11.8%
Deferred Tax Assets, Valuation Allowance 46.3M USD +136%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0 pure
Deferred Tax Assets, Gross 269M USD +30.1%
Operating Lease, Liability 13M USD
Depreciation 801K USD -23.8%
Payments to Acquire Property, Plant, and Equipment 84K USD +250%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -10.4M USD -104%
Lessee, Operating Lease, Liability, to be Paid 15.1M USD
Property, Plant and Equipment, Gross 8.64M USD +0.78%
Operating Lease, Liability, Current 2.09M USD -6.84%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.24M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 2.92M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure
Deferred Income Tax Expense (Benefit) 4.37M USD +305%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.12M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.95M USD
Deferred Tax Assets, Operating Loss Carryforwards 1.13M USD -72.2%
Unrecognized Tax Benefits 1.79M USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 3M USD
Additional Paid in Capital 935M USD +3.75%
Deferred Tax Assets, Net of Valuation Allowance 219M USD +18.2%
Share-based Payment Arrangement, Expense 29.1M USD +16.5%